Two Sigma Investments LP Sells 339,957 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT)

Two Sigma Investments LP lowered its holdings in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) by 65.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 180,465 shares of the company’s stock after selling 339,957 shares during the period. Two Sigma Investments LP owned about 0.52% of RAPT Therapeutics worth $285,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. SG Americas Securities LLC grew its holdings in shares of RAPT Therapeutics by 401.9% during the 4th quarter. SG Americas Securities LLC now owns 53,244 shares of the company’s stock valued at $84,000 after purchasing an additional 42,636 shares during the last quarter. Sei Investments Co. bought a new position in shares of RAPT Therapeutics during the 4th quarter valued at $64,000. Nuveen Asset Management LLC grew its holdings in shares of RAPT Therapeutics by 50.5% during the 4th quarter. Nuveen Asset Management LLC now owns 116,925 shares of the company’s stock valued at $185,000 after purchasing an additional 39,216 shares during the last quarter. Renaissance Technologies LLC grew its holdings in RAPT Therapeutics by 25.5% in the 4th quarter. Renaissance Technologies LLC now owns 369,736 shares of the company’s stock worth $584,000 after acquiring an additional 75,136 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in RAPT Therapeutics by 1,128.3% in the 4th quarter. JPMorgan Chase & Co. now owns 205,164 shares of the company’s stock worth $324,000 after acquiring an additional 188,461 shares during the last quarter. Institutional investors own 99.09% of the company’s stock.

RAPT Therapeutics Trading Down 7.6%

RAPT stock opened at $1.10 on Thursday. The firm’s 50-day moving average price is $0.92 and its two-hundred day moving average price is $1.12. RAPT Therapeutics, Inc. has a 12-month low of $0.71 and a 12-month high of $3.95. The stock has a market capitalization of $145.52 million, a price-to-earnings ratio of -0.40 and a beta of -0.11.

RAPT Therapeutics (NASDAQ:RAPT) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.23. Equities analysts predict that RAPT Therapeutics, Inc. will post -2.14 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. HC Wainwright upgraded shares of RAPT Therapeutics to a “strong-buy” rating and set a $6.00 price objective on the stock in a research report on Thursday, May 22nd. UBS Group decreased their price objective on shares of RAPT Therapeutics from $2.00 to $1.00 and set a “neutral” rating on the stock in a research report on Thursday, May 22nd. Finally, Wall Street Zen upgraded shares of RAPT Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, RAPT Therapeutics currently has a consensus rating of “Hold” and an average target price of $3.00.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.